Alopecia Areata
AbbVie has announced topline results for the second of its two Phase 3 clinical trials evaluating upadacitinib (RINVOQ) for alopecia areata. What is RINVOQ? The treatment is a prescription Janus kinase (JAK) inhibitor that is used to treat several conditions, like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. It is currently also being…
Inmagene Biopharmaceuticals Announces Positive Phase 2a Trial Results for IMG-007 in Alopecia Areata
Inmagene Biopharmaceuticals, a clinical-stage company focused on immunological and inflammatory diseases, has announced topline results from its Phase 2a clinical study of IMG-007 in patients with severe alopecia areata. What Is Inmagene Biopharmaceuticals? Inmagene Biopharmaceuticals was founded to advance therapies targeting immune-mediated and inflammatory conditions. The company develops novel monoclonal antibodies and small molecules, aiming…
Q32 Bio presented results from their SIGNAL-AA earlier this month at the American Academy of Dermatology (AAD) 2025 meeting for their novel alopecia areata (AA) therapy bempikibart. What is Bempikibart? Bempikibart is an experimental monoclonal antibody drug that targets two specific molecules in the body: the alpha receptor of interleukin-7 and the thymic stromal lymphopoietin…
Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…
The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults. What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…
An overview of treatments for pattern baldness and alopecia which will be in the clinical trial stage during 2023. Androgenetic Alopecia Trials Chong Kun Dang Pharmaceutical – We begin the list with a newcomer, previously unannounced. CKD-843 is a new injectable drug being trialed in “alopecia” by the Chong Kun Dang (CKD) Pharmaceutical company of Seoul,…
In this article we will cover the most prominent therapeutic candidates in the alopecia areata treatment industry in 2025. Alopecia Areata Pharmaceutical & Biotech Therapies In Development AnaptysBio – Rosnilimab or ANB030 is a Anti-PD-1 agonist. It is currently being evaluated in a 45 patient phase 2 clinical trial in moderate to severe alopecia areata.…
I’m pleased to share with you all a startup which is a little bit “outside the box” from the usual companies you’d see on Follicle Thought. Today’s topic of interest, Birch BioMed, is based in Vancouver, Canada and was birthed on the campus of the University of British Columbia. The company’s prize clinical candidate is…
According to its latest press release, Aclaris Therapeutics will be launching a phase 2 trial for the use of JAK inhibitors in androgenic alopecia (pattern hair loss) within the next few months. Here’s the line item from the press release about Aclaris’ trial in androgenic alopecia. AGA-201 Topical – a planned Phase 2 open-label clinical trial…
This article is a news feed containing brief updates of the most important hair growth treatment and hair loss cure news. It’s updated several times a week.